Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rallybio Corporaton
(NQ:
RLYB
)
1.450
+0.110 (+8.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rallybio Corporaton
< Previous
1
2
3
4
5
Next >
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
April 10, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
April 01, 2024
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 15, 2024
Via
Benzinga
Rallybio: Q4 Earnings Insights
March 12, 2024
Via
Benzinga
Where Rallybio Stands With Analysts
November 29, 2023
Via
Benzinga
Expert Ratings for Rallybio
November 10, 2023
Via
Benzinga
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
Rallybio Corporation
Via
Business Wire
Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday
February 07, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
February 06, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Where Rallybio Stands With Analysts
September 05, 2023
Via
Benzinga
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
January 04, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
December 20, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
December 09, 2023
From
Rallybio Corporation
Via
Business Wire
Analyst Ratings for Rallybio
August 10, 2023
Via
Benzinga
Analyst Ratings for Rallybio
July 25, 2023
Via
Benzinga
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
November 28, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
November 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 05, 2023
Via
Benzinga
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
October 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
September 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in September
August 31, 2023
From
Rallybio Corporation
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
October 02, 2023
On Monday, 369 companies set new 52-week lows.
Via
Benzinga
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
August 02, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
July 11, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
June 29, 2023
From
Rallybio Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.